-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ibrutinib is a first-in-class covalent Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) cells, a mechanism Plays a key role in initiating and maintaining disease and promoting its progression
.
Ibrutinib has shown significant clinical impact in patients with de novo and relapsed/refractory chronic lymphocytic leukemia (CLL), even in the setting of unfavorable cytogenetic and molecular markers
.
Ibrutinib is a first-in-class covalent Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) cells, a mechanism Plays a key role in initiating and maintaining disease and promoting its progression
In addition to the information collected in clinical trials, there is little data on the real-life use of ibrutinib, and only a few studies have mature data on its long-term outcomes, survival, and adherence to treatment
Data from all CLL patients treated with ibrutinib at the study facility were reviewed retrospectively
Figure 1: Evolution of response between interim assessment and best outcome in patients receiving first-line therapy (group (A)) and patients receiving second-line ibrutinib (group (B))
.
Figure 1: Evolution of response between interim assessment and best outcome in patients receiving first-line therapy (group (A)) and patients receiving second-line ibrutinib (group (B))
Figure 2: Progression-free survival (PFS) and overall survival (OS) curves by treatment line
.
Figure 2: Progression-free survival (PFS) and overall survival (OS) curves by treatment line
Among patients on first-line therapy, the best overall response rate (ORR) was 90.
Figure 3: Time to next treatment ((A)) for all treated patients, according to treatment line ((B))
.
Figure 3: Time to next treatment ((A)) for all treated patients, according to treatment line ((B))
In conclusion, studies have demonstrated that ibrutinib is effective and well tolerated in CLL
Original source:
Original source:Broccoli A, Argnani L, Morigi A, Nanni L, Casadei B, Pellegrini C, Stefoni V, Zinzani PL.
Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience.
Journal of Clinical Medicine .
2021 ; 10(24):5845.
https://doi.
org/10.
3390/jcm10245845
Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience.
Journal of Clinical Medicine .
2021 ; 10(24):5845.
https://doi.
org/10.
3390/jcm10245845 Broccoli A, Argnani L, Morigi A, Nanni L, Casadei B, Pellegrini C, Stefoni V, Zinzani PL.
Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience.
Journal of Clinical Medicine .
2021;10(24):5845.
https://doi.
org/10.
3390/jcm10245845 Leave a comment here
